Table 3.
Univariate analysis for local recurrence-free survival (LRFS) and disease-free survival (DFS)
| Variable | LRFS |
DFS |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Before CRT | ||||
| Age (yr) | ||||
| ≤65 vs. >65 | 1.008 (0.453–2.246) | 0.983 | 1.071 (0.628–1.827) | 0.799 |
| Sex | ||||
| Male vs. female | 1.862 (0.635–5.455) | 0.226 | 1.263 (0.709–2.246) | 0.433 |
| Body mass index (kg/m²) | ||||
| ≤25 vs. >25 | 4.770 (0.644–35.355) | 0.090 | 1.176 (0.574–2.408) | 0.651 |
| Tumor location | ||||
| Low vs. mid/upper | 2.595 (1.159–5.806) | 0.023 | 1.379 (0.787–2.418) | 0.269 |
| Tumor size (cm) | ||||
| >5 vs. ≤5 | 2.361 (1.056–5.277) | 0.039 | 1.554 (0.893–2.704) | 0.126 |
| CEA at diagnosis (ng/mL) | ||||
| >5 vs. ≤5 | 1.831 (0.819–4.089) | 0.140 | 1.499 (0.878–2.558) | 0.139 |
| mrT category | ||||
| 4 vs. 2/3 | 3.620 (1.585–8.253) | 0.003 | 2.207 (–1.238–3.933) | 0.010 |
| mrN category | ||||
| N+ vs. N0 | 3.584 (0.484–26.543) | 0.125 | 2.595 (0.809–8.318) | 0.063 |
| mrEMVI | ||||
| Yes vs. no | 9.003 (1.211–66.901 | 0.002 | 7.026 (2.184–22.593) | 0.001 |
| Differentiation | ||||
| WD vs. MD/PD | 1.228 (0.550–2.743) | 0.617 | 1.481 (0.867–2.525) | 0.151 |
| After CRT | ||||
| Tumor size at after CRT (cm) | ||||
| >5 vs. ≤5 | 3.952 (1.727–9.047) | <0.001 | 1.554 (0.893–2.704) | 0.126 |
| CEA after CRT (ng/mL) | ||||
| >5 vs. ≤5 | 2.749 (1.173–6.446) | 0.027 | 2.359 (1.065–5.223) | 0.019 |
| ymrT category | ||||
| 4 vs. 2/3 | 5.323 (2.270–12.483) | <0.001 | 2.576 (1.339–4.958) | 0.009 |
| ymrN category | ||||
| N+ vs. N0 | 2.603 (1.078–6.284) | 0.025 | 1.510 (0.880–2.590) | 0.140 |
| ymrEMVI | ||||
| Yes vs. No | 3.456 (1.476–8.091) | 0.003 | 2.665 (1.543–4.603) | <0.001 |
| ymrCRM | ||||
| Not converted vs. converted | 3.471 (1.184–10.170) | 0.010 | 2.537 (1.332–4.833) | 0.002 |
| mrTRG | ||||
| 0–2 vs. 3/4 | 6.321 (1.010–46.757) | 0.015 | 2.720 (1.083–6.831) | 0.014 |
| Pathologic variable | ||||
| Surgery type | ||||
| SSS vs. SPS | 2.716 (1.071–6.884) | 0.054 | 1.538 (0.723–3.271) | 0.287 |
| Lymphovascular invasion | ||||
| Yes vs. no | 2.397 (0.949–6.056) | 0.088 | 1.435 (0.700–2.941) | 0.343 |
| Perineural invasion | ||||
| Yes vs. no | 3.032 (1.345–6.835) | 0.007 | 1.510 (0.880–2.590) | 0.140 |
| Pathologic CRM | ||||
| Involved vs. not involved | 10.325 (4.258–25.033) | <0.001 | 3.472 (2.020–5.965) | <0.001 |
| Pathologic T | ||||
| 3/4 vs. 0–2 | 2.864 (0.672–12.210) | 0.100 | 3.437 (1.239–9.534) | 0.004 |
| Pathologic N | ||||
| Yes vs. No | 2.608 (1.114–6.103) | 0.022 | 2.175 (1.225–4.844) | 0.015 |
| Distal margin (cm) | ||||
| <1 vs. ≥1 | 0.864 (0.257–2.902) | 0.810 | 1.037 (0.467–2.301) | 0.928 |
| Pathologic TRG | ||||
| 0–2 vs. 3/4 | 1.516 (0.676–3.399) | 0.314 | 1.001 (0.577–1.735) | 0.998 |
CRM, circumferential resection margin; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; EMVI, extramural venous invasion; HR, hazard ratio; CI, confidence interval; mrTRG, magnetic resonance imaging tumor regression grade; LAR, low anterior resection; ISR, intersphincteric resection; APR, abdominoperineal resection; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; TRG, tumor regression grade.